Quantcast

Latest G protein-coupled receptor Stories

2014-09-16 04:21:23

LONDON and BOSTON, September 16, 2014 /PRNewswire/ -- Heptares Therapeutics notes that its Chief Scientific Officer, Fiona Marshall, will give a presentation entitled "Structure-based Drug Design for G protein-coupled receptors using StaR(R) technology" as part of the inaugural "Advances in Drug Discovery and Development" virtual symposium run by Chemical & Engineering News, a publication of the American Chemical Society. The virtual symposium is on Wednesday, 24 September...

2014-09-03 08:33:44

Experienced Financial and Operational Leader to Support Global Development of Novel Monoclonal Antibody Therapeutics to GPCRs LA JOLLA, Calif. and SHANGHAI, Sept. 3, 2014 /PRNewswire/ -- RuiYi, Inc., a global therapeutic innovation leader, announced today the appointment of Mark Saad as chief financial officer (CFO). Mr. Saad is a skilled financial and operations leader and was most recently CFO at Cytori Therapeutics for the past ten years. At RuiYi, he will play a critical...

2014-08-08 08:25:41

SEATTLE, Aug. 8, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference in New York next week. The presentation is scheduled for Tuesday,...

2014-06-30 04:21:39

LONDON and BOSTON, June 30, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is delighted to announce that Fiona Marshall, Heptares' Chief Scientific Officer and co-founder, has been invited to present at the Royal Society of Medicine Medical Innovations Summit. The event, which takes place on Saturday 5 July 2014 at The Royal Society of Medicine in London, UK, will feature presentations on pioneering...

2014-06-24 12:28:56

LONDON and BOSTON, June 24, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that its President, Dan Grau, will present a company overview at the JMP Securities Healthcare Conference (24-25 June 2014, New York, NY, USA). His presentation will take place on 25 June at 9.30 am EDT. For a full list of events at which Heptares will be present, please visit http://www.heptares.com About...

2014-06-23 13:34:53

Duke University Medical Center A team of scientists from Duke Medicine, the University of Michigan and Stanford University has determined the underlying architecture of a cellular signaling complex involved in the body's response to stimuli such as light and pain. This complex, consisting of a human cell surface receptor and its regulatory protein, reveals a two-step mechanism that has been hypothesized previously but not directly documented. The findings, reported on June 22, 2014,...

2014-06-11 08:29:19

LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, Inc., a global therapeutic innovation leader, announced today the close of a $4 million debt financing from Silicon Valley Bank to advance a pipeline of novel monoclonal antibodies (mAb) targeting G protein coupled receptors (GPCRs). RuiYi plans to file an IND and initiate clinical trials in multiple countries in 2015 for the company's lead asset, RYI-008, a novel anti-IL-6 mAb for rheumatoid arthritis and cancer....

2014-06-11 08:29:17

New antibodies generated with RuiYi's iCAPS technology to explore GPCR structure and function LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, a global therapeutic innovation leader, and iHuman Institute at ShanghaiTech University announced today a new research collaboration applying RuiYi's iCAPS (Intermembranous Conformation Antigen Presenting System) technology to create novel monoclonal antibodies with specific binding to G protein coupled receptors (GPCRs) to...

2014-05-29 04:22:16

LONDON and BOSTON, May 29, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Malcolm Weir, Heptares' Chief Executive Officer and co-founder, will give a company presentation at the Jefferies 2014 Global Healthcare in New York City, NY, USA. The presentation will take place at 9:00am EDT on Monday 2 June. In addition, Heptares will give presentations at the following industry and scientific...

2014-05-15 04:22:26

LONDON and BOSTON, May 15, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Fiona Marshall, Heptares' Chief Scientific Officer and co-founder, will give a company presentation at the UBS Global Healthcare Conference [https://www.ubs.com/global/en/investment-bank/key-investor-conferences/americas.html ] in New York City, NY, USA. The presentation will take place at 9:00am EDT on Monday 19 May....


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.